BTIG analyst Kaveri Pohlman assigned a Buy rating to Gritstone Oncology (GRTS – Research Report) on January 4 and set a price target of $20.00. The company’s shares closed last Thursday at $6.73, close to its 52-week low of $3.00.
According to TipRanks.com, Pohlman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -24.3% and a 12.5% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Checkmate Pharmaceuticals, and Mersana Therapeutics.
Currently, the analyst consensus on Gritstone Oncology is a Moderate Buy with an average price target of $17.50, implying a 171.0% upside from current levels. In a report issued on January 5, H.C. Wainwright also maintained a Buy rating on the stock with a $24.00 price target.
The company has a one-year high of $35.20 and a one-year low of $3.00. Currently, Gritstone Oncology has an average volume of 1.7M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.
Read More on GRTS: